CRISPR THERAPEUTICS AG (CRSP)

Every figure this model derived for CRSP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,743,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 2,364,352,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 2,371,770,000 AssetsCurrent 2026-06-30
current liabilities 132,896,000 LiabilitiesCurrent 2026-06-30
equity 1,746,551,000 StockholdersEquity 2026-06-30
interest expense 3,877,000 InterestExpenseDebt 2026-06-30
ocf -369,582,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 13,392,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 68,320,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CRSP on one particular measure came for.

RatioValue
current ratio20.15
current ratio reported17.85
deferred revenue growth613.43
dilution pct6.6
growth cv1.56
interest cover-137.82
revenue growth-64.8
revenue growth per share-66.98
rule of 40-4054.8
sbc pct revenue510.16

What to be careful about

What this model itself distrusts about CRSP's figures. Written by the derivation as it ran, not added afterwards.